HNSBF Quote, Financials, Valuation and Earnings

BioInvent International AB has a net margin of -217.19% compared to Hansa Biopharma AB's net margin of -4171.4%. Hansa Biopharma AB's return on equity of -- beat BioInvent International AB's return on equity of -45.16%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than BioInvent International AB, analysts believe Hansa Biopharma AB is more attractive than BioInvent International AB.

Hansa Biopharma AB has a beta of 0.490, which suggesting that the stock is 50.963% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.984%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $8.1M, which are larger than BioInvent International AB quarterly revenues of $320.6K. Hansa Biopharma AB's net income of -$17.5M is lower than BioInvent International AB's net income of -$13.4M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 10.42x versus 9.32x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.

BioArctic AB has a net margin of -217.19% compared to Hansa Biopharma AB's net margin of -4.8%. Hansa Biopharma AB's return on equity of -- beat BioArctic AB's return on equity of 52.54%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioArctic AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than BioArctic AB, analysts believe Hansa Biopharma AB is more attractive than BioArctic AB.

Hansa Biopharma AB has a beta of 0.490, which suggesting that the stock is 50.963% less volatile than S&P 500. In comparison BioArctic AB has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioArctic AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. BioArctic AB pays out 17.32% of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hansa Biopharma AB quarterly revenues are $8.1M, which are smaller than BioArctic AB quarterly revenues of $19.6M. Hansa Biopharma AB's net income of -$17.5M is lower than BioArctic AB's net income of -$938.5K. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while BioArctic AB's PE ratio is 30.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 10.42x versus 14.99x for BioArctic AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -217.19% compared to Hansa Biopharma AB's net margin of 21.72%. Hansa Biopharma AB's return on equity of -- beat Camurus AB's return on equity of 19.19%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Camurus AB, analysts believe Hansa Biopharma AB is more attractive than Camurus AB.

Hansa Biopharma AB has a beta of 0.490, which suggesting that the stock is 50.963% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.17%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $8.1M, which are smaller than Camurus AB quarterly revenues of $49.4M. Hansa Biopharma AB's net income of -$17.5M is lower than Camurus AB's net income of $10.7M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Camurus AB's PE ratio is 44.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 10.42x versus 14.30x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of -217.19% compared to Hansa Biopharma AB's net margin of -3503.14%. Hansa Biopharma AB's return on equity of -- beat Orexo AB's return on equity of -134.37%.

Hansa Biopharma AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that Hansa Biopharma AB has higher upside potential than Orexo AB, analysts believe Hansa Biopharma AB is more attractive than Orexo AB.

Hansa Biopharma AB has a beta of 0.490, which suggesting that the stock is 50.963% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.999%.

Hansa Biopharma AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hansa Biopharma AB pays -- of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend.

Hansa Biopharma AB quarterly revenues are $8.1M, which are larger than Orexo AB quarterly revenues of $350.8K. Hansa Biopharma AB's net income of -$17.5M is lower than Orexo AB's net income of -$12.3M. Notably, Hansa Biopharma AB's price-to-earnings ratio is -- while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hansa Biopharma AB is 10.42x versus 2.04x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.